Advertisement

Journal of Neuroinflammation

, 15:266 | Cite as

NLRP3 inflammasome-dependent pyroptosis is proposed to be involved in the mechanism of age-dependent isoflurane-induced cognitive impairment

  • Lei Yin
  • Fangping Bao
  • Jing Wu
  • Kuanyu Li
Open Access
Letter to the Editor

Abstract

Wang Z et al. recently published a paper, titled “Critical role of NLRP3-caspase-1 pathway in age-dependent isoflurane-induced microglial inflammatory response and cognitive impairment”. The finding in this paper is consistent with our previous study on NLRP3-caspase-1 pathway. Here, we propose that NLRP3 inflammasome-dependent pyroptosis may be involved in the mechanism of age-dependent isoflurane-induced cognitive impairment and discuss that inhibiting NLRP3 inflammasome activation with a novel inhibitor MCC950 may ameliorate age-dependent isoflurane-induced neuro-inflammation.

Keywords

Isoflurane Cognition NLRP3 MCC950 Pyroptosis 

Abbreviations

IL-18

Interleukin-18

IL-1β

Interleukin-1β

NLRP3

NOD-like receptor protein 3

TNF-α

Tumor necrosis factor-α

Letter to the editor

Recently, we read with great interest the article titled “Critical role of NLRP3-caspase-1 pathway in age-dependent isoflurane-induced microglial inflammatory response and cognitive impairment” by Dr. Wang Z et al. [1], who concluded that NLRP3 priming status in aged mouse brain may be involved in isoflurane-induced hippocampal inflammation and cognitive impairment. We appreciate this study and would like to present our opinion on it.

The NLRP3 inflammasome-caspase-1 pathway has been implicated in several metabolic and inflammatory diseases [2, 3]. It is also proposed to be a possible pathogenic mechanism for general anesthesia-induced neuro-inflammation and cognitive impairment [4, 5]. We have previously shown that isoflurane induces activation of NLRP3, cleavage of caspase 1, and increase of IL-1β and TNF-α levels in the hippocampus of aging mice and supposed that inhibiting the NLRP3 inflammasome might have therapeutic merit for ameliorating general anesthesia-induced cognitive deficits [5] as cited in Wang’s study. However, the selective inhibitor of NLRP3 inflammasome was lacking. Interestingly, in Wang’s study, they demonstrated that treatment of Ac-YVAD-cmk, an inhibitor of NLRP3-caspase-1, reversed isoflurane-induced microglial inflammatory response and cognitive impairment in aged mice [1]. This finding is a very important evidence for supporting that NLRP3-caspase-1 pathway is involved in the mechanism of general anesthesia-induced cognitive impairment. However, Ac-YVAD-cmk is a specific inhibitor of caspase-1, not of NLRP3 inflammasome. It is uncertain whether cleavage of caspase-1 directly results from NLRP3 inflammasome activation and results in the secretion of the pro-inflammatory IL-1β and IL-18 in Wang’s study [1, 6, 7]. The treatment of aging mice with NLRP3 inflammasome inhibitor will be needed. MCC950 is a highly potent specific NLRP3 inhibitor and was first introduced as a specific anti-inflammatory compound since 2015 [8]. The novel compound MCC950 has been clearly shown to be neuroprotective in multiple neurological disorders, including ischemic and degenerative diseases [9, 10]. Although MCC950 has not been used in general anesthesia issues, we think that it is promising as a therapeutic compound for treatment of general anesthesia-induced neuro-inflammation and cognitive impairment.

Pyroptosis is a novel inflammatory form of programmed cell death that has been discovered and verified recently. This type of cell death is characterized to be NLRP3 inflammoasome-caspase-1 dependent [11, 12, 13]. Recent advances strongly hint that pyroptosis plays a regulatory role in many infectious and noninfectious diseases [11], and MCC950 can inhibit NLRP3 inflammasome to further prevent pyroptosis [12]. However, little is known about the functions of pyroptosis in general anesthesia-induced neurotoxicity, and thus, an effective intervention, MCC950, is emerging. Wang’s study found that isoflurane activated NLRP3-caspase-1 pathway and increased the secretion of IL-18 and IL-1β in cells pretreated with lipopolysaccharide and suggested that isoflurane induces age-related hippocampal inflammation through NLRP3-caspase-1 pathway. In this regard, we present a hypothesis that pyroptosis plays a critical role in the mechanism of isoflurane-induced cognitive impairment and MCC950 inhibits the NLRP3 inflammasome-dependent pyroptosis in isoflurane anesthesia to improve the cognition.

Collectively, we present our hypothesis that NLRP3 inflammasome-dependent pyroptosis may be involved in the mechanism of age-dependent isoflurane-induced cognitive impairment, and inhibition of the NLRP3 inflammasome activation with MCC950 may ameliorate age-dependent isoflurane-induced neuro-inflammation. Future studies are needed to confirm the hypothesis.

We again compliment the authors on their excellent article and thank them for their contribution to it.

Notes

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Authors’ contributions

LY and JW wrote the first draft of the paper. FB and KL contributed to the writing of the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Wang Z, Meng S, Cao L, Chen Y, Zuo Z, Peng S. Critical role of NLRP3-caspase-1 pathway in age-dependent isoflurane-induced microglial inflammatory response and cognitive impairment. J Neuroinflammation. 2018;15:109.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Chen W, Foo SS, Zaid A, Teng TS, Herrero LJ, Wolf S, Tharmarajah K, Vu LD, van Vreden C, Taylor A, et al. Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation. Nat Microbiol. 2017;2:1435–45.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Lee HJ, Hong YS, Jun W, Yang SJ. Nicotinamide riboside ameliorates hepatic metaflammation by modulating NLRP3 inflammasome in a rodent model of type 2 diabetes. J Med Food. 2015;18:1207–13.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Li XM, Zhou MT, Wang XM, Ji MH, Zhou ZQ, Yang JJ. Resveratrol pretreatment attenuates the isoflurane-induced cognitive impairment through its anti-inflammation and -apoptosis actions in aged mice. J Mol Neurosci. 2014;52:286–93.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Wu J, Li H, Sun X, Zhang H, Hao S, Ji M, Yang J, Li K. A mitochondrion-targeted antioxidant ameliorates isoflurane-induced cognitive deficits in aging mice. PLoS One. 2015;10:e0138256.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Wang L, Fu H, Nanayakkara G, Li Y, Shao Y, Johnson C, Cheng J, Yang WY, Yang F, Lavallee M, et al. Novel extracellular and nuclear caspase-1 and inflammasomes propagate inflammation and regulate gene expression: a comprehensive database mining study. J Hematol Oncol. 2016;9:122.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell. 2016;165:792–800.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248–55.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Qi Y, Klyubin I, Cuello AC, Rowan MJ. NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo. Neurobiol Dis. 2018;114:24–30.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Ye X, Shen T, Hu J, Zhang L, Zhang Y, Bao L, Cui C, Jin G, Zan K, Zhang Z, et al. Purinergic 2X7 receptor/NLRP3 pathway triggers neuronal apoptosis after ischemic stroke in the mouse. Exp Neurol. 2017;292:46–55.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Jiang DL, Chen S, Sun RY, Zhang X, Wang D. The NLRP3 inflammasome: role in metabolic disorders and regulation by metabolic pathways. Cancer Lett. 2018;419:8–19.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Dempsey C, Rubio Araiz A, Bryson KJ, Finucane O, Larkin C, Mills EL, Robertson AAB, Cooper MA, O'Neill LAJ, Lynch MA. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1 mice. Brain Behav Immun. 2017;61:306–16.CrossRefGoogle Scholar
  13. 13.
    Wu DD, Pan PH, Liu B, Su XL, Zhang LM, Tan HY, Cao Z, Zhou ZR, Li HT, Li HS, et al. Inhibition of alveolar macrophage pyroptosis reduces lipopolysaccharide-induced acute lung injury in mice. Chin Med J. 2015;128:2638–45.CrossRefPubMedCentralGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of AnesthesiologyShanghai Pudong New Area People’s HospitalShanghaiChina
  2. 2.Wannan Medical CollegeAnhuiChina
  3. 3.Department of Anesthesiology, The First Affiliated Hospital, College of MedicineZhejiang UniversityHangzhouChina
  4. 4.Jiangsu Key Laboratory of Molecular MedicineMedical School of Nanjing UniversityNanjingChina

Personalised recommendations